Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 4
2005 9
2006 9
2007 8
2008 4
2009 1
2010 3
2011 3
2012 3
2013 2
2014 2
2015 2
2016 2
2017 3
2018 3
2019 4
2020 6
2021 3
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers.
Yoshihara K, Fukae M, Kastrissios H, Wada R, Shimizu T, Ishizuka H. Yoshihara K, et al. Among authors: shimizu t. Drug Metab Pharmacokinet. 2023 Oct;52:100516. doi: 10.1016/j.dmpk.2023.100516. Epub 2023 Jun 7. Drug Metab Pharmacokinet. 2023. PMID: 37690271 Free article.
Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies.
Tachibana M, Matsuki S, Toyama K, Maekawa Y, Fukae M, Shimizu T, Tsutsumi J, Shinohara S, Ishizuka H. Tachibana M, et al. Among authors: shimizu t. Clin Pharmacol Drug Dev. 2024 Jan;13(1):77-86. doi: 10.1002/cpdd.1315. Epub 2023 Aug 11. Clin Pharmacol Drug Dev. 2024. PMID: 37565616 Clinical Trial.
Correction to: Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
Watanabe A, Ishizuka T, Yamada M, Igawa Y, Shimizu T, Ishizuka H. Watanabe A, et al. Among authors: shimizu t. Eur J Clin Pharmacol. 2022 Jan;78(1):75. doi: 10.1007/s00228-021-03211-z. Eur J Clin Pharmacol. 2022. PMID: 34494163 Free PMC article. No abstract available.
Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
Watanabe A, Ishizuka T, Yamada M, Igawa Y, Shimizu T, Ishizuka H. Watanabe A, et al. Among authors: shimizu t. Eur J Clin Pharmacol. 2022 Jan;78(1):65-73. doi: 10.1007/s00228-021-03194-x. Epub 2021 Aug 20. Eur J Clin Pharmacol. 2022. PMID: 34415382 Free PMC article. Clinical Trial.
Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.
Toyama K, Furuie H, Kuroda K, Ishizuka T, Okuda Y, Shimizu T, Kato M, Igawa Y, Nishikawa Y, Ishizuka H. Toyama K, et al. Among authors: shimizu t. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):685-694. doi: 10.1007/s13318-021-00701-4. Epub 2021 Aug 12. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34383278 Free PMC article. Clinical Trial.
74 results